Deleted in press. 330. Ghali JK, Koren MJ, Taylor JR, et al. Ef cacy and safety of oral con- ivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91: 2145 52. 331. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099 112. 332. Naylor M, Brooten D, Jones R, et al. Comprehensive discharge planning for the hospitalized elderly: a randomized clinical trial. Ann Intern Med 1994;120:999 1006. 333. Naylor MD, Brooten DA, Campbell RL, et al. Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial. J Am Geriatr Soc 2004;52:675 84. 334. Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: ndings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007;153: 1021 8. Yancy et al. JACC Vol. 62, No. 16, 2013 2013 ACCF/AHA Heart Failure Guidelines: Executive Summary October 15, 2013:1495 539 335. Fonarow GC, Abraham WT, Albert NM, et al. In uence of a perfor- mance-improvement initiative on quality of care for patients hospital- ized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 2007;167:1493 502. 336. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patientsat high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004;44:810 9. 337. Lappe JM, Muhlestein JB, Lappe DL, et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med 2004;141:446 53. 338. Phillips CO, Wright SM, Kern DE, et al. 